Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production
Abatacept may exert its clinical effect on rheumatoid arthritis (RA) by suppressing anti-cyclic citrullinated peptide (CCP) antibody production. This study was undertaken to test this hypothesis by examining the changes of disease activity of RA and anti-CCP antibody levels over time after starting...
Main Authors: | Hisakata Yamada, Tomomi Tsuru, Takeshi Otsuka, Masayuki Maekawa, Hiroshi Harada, Takaaki Fukuda, Hiroshi Tsukamoto, Akira Maeyama, Shigeru Yoshizawa, Ken Wada, Yasuharu Nakashima, Eisuke Shono, Seiji Yoshizawa, Hiroshi Jojima, Masakazu Kondo |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-04-01
|
Series: | Immunological Medicine |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/25785826.2020.1718833 |
Similar Items
-
Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis
by: Noriyoshi Ogawa, et al.
Published: (2019-01-01) -
The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study
by: Paul Emery, et al.
Published: (2023-04-01) -
Epitope Specificity of Anti-Citrullinated Protein Antibodies
by: Nicole H. Trier, et al.
Published: (2017-03-01) -
ABATACEPT FOR RHEUMATOID ARTHRITIS: A NOVEL FORMULATION, NEW MECHANISMS, NEW POSSIBILITIES
by: E. L. Nasonov
Published: (2015-10-01) -
Specificity of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis
by: Nicole H. Trier, et al.
Published: (2019-06-01)